Subcutaneous Recombinant Human IL-15 (s.c. rhIL-15) and Alemtuzumab for People With Refractory or Relapsed Chronic and Acute Adult T-cell Leukemia (ATL)

Clinical trial NCT02689453 · COMPLETED

Trial details

NCT number: NCT02689453
Sponsor: National Cancer Institute (NCI)
Status: COMPLETED
Phase: Phase 1
Study type: INTERVENTIONAL

T-Cell Lymphoma Relapsed Adult T-Cell Leukemia (ATL)Peripheral T-Cell Lymphoma (PTCL)Cutaneous T Cell Lymphoma (CTCL)T-Cell Prolymphocytic Leukemia

Start date: 2017-01-19
Primary completion: 2021-06-15
Enrollment: 11

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.